Ignite Creation Date:
2024-05-06 @ 7:27 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06014944
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-31
First Post:
2023-07-28
Brief Title:
Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody
Sponsor:
Changhai Hospital
Organization:
Changhai Hospital
Study Overview
Official Title:
A Single-arm Single-center Prospective Clinical Study of Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody for Neoadjuvant Therapy of PMMRMSS Type Middle and Low Locally Advanced Rectal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PMMRMSS
Brief Summary:
The investigators conduct a single-arm single-center prospective clinical study enrolling patients diagnoses with pMMR MSS type middle and low locally advanced rectal cancer who had not received systemic anti-tumor therapy to explore the efficacy and safety of short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody as neoadjuvant therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None